Frederick Hudson Sells 5,369 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Frederick Hudson sold 5,369 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $50.61, for a total value of $271,725.09. Following the completion of the transaction, the director directly owned 60,413 shares in the company, valued at approximately $3,057,501.93. The trade was a 8.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock traded up $0.30 during mid-day trading on Monday, reaching $50.21. 517,222 shares of the company were exchanged, compared to its average volume of 762,366. The business’s 50 day simple moving average is $51.22 and its 200 day simple moving average is $49.10. The company has a market capitalization of $2.89 billion, a P/E ratio of -73.84, a P/E/G ratio of 1.55 and a beta of 0.70. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $59.68.

Wall Street Analyst Weigh In

SUPN has been the subject of several recent analyst reports. Stifel Nicolaus raised their price objective on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a report on Friday, December 19th. Zacks Research lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Sunday, March 8th. Finally, Craig Hallum set a $65.00 price objective on Supernus Pharmaceuticals in a report on Wednesday, February 25th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $62.17.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in SUPN. Hantz Financial Services Inc. increased its stake in Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 281 shares during the last quarter. Torren Management LLC bought a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth about $49,000. USA Financial Formulas acquired a new position in shares of Supernus Pharmaceuticals in the 3rd quarter valued at about $50,000. EverSource Wealth Advisors LLC acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at about $51,000. Finally, Smartleaf Asset Management LLC grew its position in shares of Supernus Pharmaceuticals by 30.8% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 268 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.